368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumorsAdi Diab, Sandra P. D’Angelo, Evidio Domingo‐Musibay et al.|Regular and Young Investigator Award Abstracts|2020Cited by 15
355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignanciesNina Shah, Krina K. Patel, Alan Tan et al.|Regular and Young Investigator Award Abstracts|2020Cited by 3